Data from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
Martin Filipits(University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Knauer(Breast Center), Sean Ferree(Hospital Costa del Sol), Shuzhen Liu(Qingdao University), Peter Regitnig(Medical University of Graz), Christine Gruber-Rossipal, Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Harald Trapl(Medical University of Graz), Richard Greil(Paracelsus Medical University), Thomas Bauernhofer, Margaretha Rudas(Comprehensive Cancer Center Vienna), Torsten O. Nielsen(University of British Columbia), Carl Schaper(Hospital Costa del Sol), Peter Dubsky(Hirslanden Klinik St. Anna), Brigitte Mlineritsch(Paracelsus Medical University), Michael Hubalek(Innsbruck Medical University), Otto Dietze(Medical University of Graz), J. Wayne Cowens(Nanostring Technologies (United States)), Herbert Stöger(Medical University of Graz), Elisabeth Müller‐Holzner(Medical University of Graz), R. Jakesz(Comprehensive Cancer Center Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 0
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k